The company is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms to develop new medicines with improved, durable, and potentially curative clinical outcomes, including CARs, TILs, and TCRs. Lyell's ultimate goal is to develop curative cell-based therapies for solid tumor cancers, which represent the vast majority of cancers and have yet to show substantial benefit with cell-based immunotherapies.